Biotechnology Today
more-
Terns’ ex-MASH drug cuts fat, not muscle or food intake, in GLP-1 combo in mice
Terns Pharmaceuticals’ prediction that its shelved metabolic dysfunction-associated steatohepatitis (MASH) drug TERN-501 could be effective…
ADA: Continuous glucose monitors, smart insulin pumps make their case for Type 2 diabetes
Merck KGaA drops xevinapant with phase 3 head and neck cancer trial on course for failure
When the Wegovy stops, the weight gain restarts. Could a GLP-1 gene therapy change that?
Takeda’s anti-CD38 antibody on track for phase 3 after boosting platelet count in bleeding disorder
Markets
more-
Weekly Market Review – September 28, 2024
Stock Markets Stocks hit new record highs this week on the back of optimism about…
Bio Space
more
The end of eFFECTOR Therapeutics: Oncology biotech winds down after midstage fail
It’s the end of an era—eFFECTOR Therapeutics’ era to be…
mRNA, genomic medicines biotech Exsilio breaks cover with $82M and Tal Zaks at the helm
If you’re going to be a new biotech in mRNA,…
Illumina parts ways with Grail, with divestiture complete
Nearly four years after first pitching its multibillion-dollar plan to…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
Terns’ ex-MASH drug cuts fat, not muscle or food intake, in GLP-1 combo in mice
ADA: Continuous glucose monitors, smart insulin pumps make their case for Type 2 diabetes
Merck KGaA drops xevinapant with phase 3 head and neck cancer trial on course for failure
When the Wegovy stops, the weight gain restarts. Could a GLP-1 gene therapy change that?
The end of eFFECTOR Therapeutics: Oncology biotech winds down after midstage fail
mRNA, genomic medicines biotech Exsilio breaks cover with $82M and Tal Zaks at the helm
Illumina parts ways with Grail, with divestiture complete
Amylyx seeks to fill Relyvrio-sized hole in pipeline with $35M GLP-1 buy
Takeda’s anti-CD38 antibody on track for phase 3 after boosting platelet count in bleeding disorder
Novo Nordisk unwraps phase 3 hemophilia A data, revealing how Roche rivalry may shake out